Toronto Dominion Bank’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-40,000
Closed -$4.88M 2440
2025
Q4
$4.88M Buy
+40,000
New +$4.59M 0.01% 853
2025
Q3
Sell
-233,700
Closed -$19.4M 2117
2025
Q2
$19.4M Buy
233,700
+203,700
+679% +$16.3M 0.03% 394
2025
Q1
$2.43M Hold
30,000
﹤0.01% 890
2024
Q4
$2.7M Buy
+30,000
New +$2.91M ﹤0.01% 853
2024
Q1
Sell
-50,000
Closed -$4.46M 1629
2023
Q4
$4.46M Hold
50,000
0.01% 717
2023
Q3
$3.65M Hold
50,000
0.01% 761
2023
Q2
$4.16M Hold
50,000
0.01% 748
2023
Q1
$3.81M Sell
50,000
-50,000
-50% -$4.15M 0.01% 744
2022
Q4
$8.31M Hold
100,000
0.01% 562
2022
Q3
$7.94M Buy
+100,000
New +$8.43M 0.01% 548

Other funds holding XBI

Toronto Dominion Bank's XBI Position: Q1 2026 in Review

Toronto Dominion Bank reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 100% in Q1 2026, selling an estimated $1.24M and leaving 17 shares worth $2.12K. The position accounts for ﹤0.01% of the portfolio, ranked #2004.

Toronto Dominion Bank first reported a position in XBI in Q2 2013 and has held it in 50 quarters since. The position peaked at $864M in Q2 2021. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

  • Toronto Dominion Bank held 17 shares of State Street SPDR S&P Biotech ETF worth $2.12K as of Q1 2026.
  • Toronto Dominion Bank sold 9,914 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $1.24M.
  • State Street SPDR S&P Biotech ETF made up ﹤0.01% of Toronto Dominion Bank's portfolio in Q1 2026, its #2004 holding.
  • Toronto Dominion Bank first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and has held it in 50 quarters since.
  • Toronto Dominion Bank's State Street SPDR S&P Biotech ETF position peaked at $864M in Q2 2021.
  • 814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Toronto Dominion Bank's 13F filing for Q1 2026, filed 15 May 2026.